Tissue Factor-Targeted "O₂-Evolving" Nanoparticles for Photodynamic Therapy in Malignant Lymphoma

Area of Science:

• Biomedical Engineering
• Nanomedicine
• Oncology

Background:

• Vascular-targeted photodynamic therapy (vPDT) shows promise for cancers but faces challenges in lymphoma due to hypoxia and lack of specific targets.
• Lymphoma's hypoxic microenvironment and undefined therapeutic targets limit vPDT efficacy.

Purpose of the Study:

• To develop an "O2-evolving" nanoparticle strategy targeting lymphoma vasculature to enhance vPDT efficacy.
• To investigate the combined therapeutic effect of vPDT and novel nanoparticles in lymphoma models.

Main Methods:

• Designed catalase and HMME-encapsulated nanoparticles (CENPs) modified with EGFP-EGF1 for lymphoma targeting.
• Evaluated CENP accumulation in lymphoma vasculature in vitro and in vivo.
• Assessed the impact of combined vPDT and CENPs on lymphoma glucose metabolism and hypoxia-inducible factor (HIF)-1α expression using PET imaging.

Main Results:

• CENPs demonstrated effective accumulation in lymphoma vasculature, which was enhanced by PDT treatment.
• Combined vPDT and CENPs significantly inhibited lymphoma glucose metabolism.
• Hypoxia-inducible factor (HIF)-1α expression was markedly reduced in groups receiving entrapped catalase.

Conclusions:

• The developed "O2-evolving" nanoparticle strategy effectively targets lymphoma vasculature via tissue factor.
• Combined vPDT and CENPs promote self-oxygen supply, overcoming hypoxia and demonstrating significant therapeutic effects against malignant lymphoma.